Abstract:Aging is a natural process with concomitant changes in the gut microbiota and associate metabolomes. Beta-nicotinamide mononucleotide, an important NAD + intermediate, has drawn increasing attention to retard the aging process. We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN). Considering the telomere length as a molecular gauge for aging, we measured this in the peripheral blood mononuclear cells (PBMC) of pre-aging mice and human volunteers (age: 45–60 years old). Notably, the NMN administration did not influence the body weight and feed intake significantly during the 40 days in pre-aging mice. Metabolomics suggested 266 upregulated and 58 downregulated serum metabolites. We identified 34 potential biomarkers linked with the nicotinamide, purine, and proline metabolism pathways. Nicotinamide mononucleotide significantly reduced the fecal bacterial diversity ( p < 0.05) with the increased abundance of Helicobacter, Mucispirillum , and Faecalibacterium , and lowered Akkermansia abundance associated with nicotinamide metabolism. We propose that this reshaped microbiota considerably lowered the predicated functions of aging with improved immune and cofactors/vitamin metabolism. Most notably, the telomere length of PBMC was significantly elongated in the NMN-administered mice and humans. Taken together, these findings suggest that oral NMN supplementation in the pre-aging stage might be an effective strategy to retard aging. We recommend further studies to unravel the underlying molecular mechanisms and comprehensive clinical trials to validate the effects of NMN on aging.

Research advances in the function and anti-aging effects of nicotinamide mononucleotide

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer’s Disease

Β-Nicotinamide Mononucleotide Supplementation Prolongs the Lifespan of Prematurely Aged Mice and Protects Colon Function in Ageing Mice.

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions

Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns

Advancements in NMN biotherapy and research updates in the field of digestive system diseases

Nicotinamide mononucleotide: An emerging nutraceutical against cardiac aging?

Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-Aged and Elderly: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions

Nicotinamide Mononucleotide (NMN) as a Solution of Decrease Nicotinamide Adenine Dinucleotide (NAD+) in Aging

EFFICACY OF NICOTINAMIDE MONONUCLEOTIDE SUPPLEMENTATION (NMN) IN BLOOD NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) FOR ANTI-AGING IN ADULTS: A SYSTEMATIC REVIEW

Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD Plus Metabolism

Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process

Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide. Novel approaches for better aging

Technology and functional insights into the nicotinamide mononucleotide for human health

NMN Nicotinamide Mononucleotide Activates Intracellular Energy and Approaches the Prevention and Improvement of Aging

The Impacts of Short-Term NMN Supplementation on Serum Metabolism, Fecal Microbiota, and Telomere Length in Pre-Aging Phase

Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases

Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide

[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].